A Smart + Strong Site
Subscribe to:
POZ magazine

Back to home » Treatment News » Top Stories

Most Popular Stories
Undetectable Viral Load Essentially Eliminates Transmission Risk in Straight Couples
FDA Approves New Single-Tablet HIV Regimen, Triumeq
Life Expectancy for Young People With HIV Is Nearly Normal
A 15-Year Jump in Life Expectancy for People With HIV
Scientists Devise Method of Snipping HIV From Immune Cells
Monkey HIV Vaccine Success Opens Door for Human Trials
HIV Combo Pill Less Toxic Thanks to New Form of Tenofovir
What's That Mean?
(just double-click it!)

If you don't understand one of the words in this article, just double-click it. A window will open with a definition from mondofacto's On-line Medical Dictionary. If the double-click feature doesn't work in your browser, you can enter the word below:

Most Popular Lessons
Aging & HIV
The HIV Life Cycle
Herpes Simplex Virus
Syphilis & Neurosyphilis
Treatments for Opportunistic Infections (OIs)
What is AIDS & HIV?
More News

Have medical or treatment news about HIV? Send press releases, news tips and other announcements to news@aidsmeds.com.

Click here for more news


July 23, 2012

HPTN 052 Follow Up: No Increase in Unsafe Sex; Continued Viral Suppression

by Laura Whitehorn

AIDS 2012Follow-up data from HIV Prevention Trials Network Study 052 (HPTN 052) show that HIV-serodiscordant couples, in which the positive partner is receiving antiretroviral (ARV) therapy, are no more likely to abandon safer sex practices over time, according to a report presented Monday, July 23, at the XIX International AIDS Conference (AIDS 2012) in Washington, DC.

The researchers, led by Kenneth Mayer, MD, of Boston’s Fenway Community Health Center, also reported that viral loads remained suppressed in the vast majority of the HIV-positive partners during the two-year follow-up period.

HPTN 052, which began in April 2005, enrolled 1,763 HIV-serodiscordant couples, most of whom (97 percent) were heterosexual. The purpose was to measure whether immediate versus delayed use of ARV therapy by the HIV-positive partner would reduce transmission of the virus to the negative partner. The study was also meant to evaluate whether beginning ARV treatment earlier would benefit the health of the HIV-positive partner.

In the large international trial, 886 HIV-positive participants were randomized to start ARV therapy right away (the immediate treatment group), while 877 waited until their CD4s dropped to 250 or they developed an AIDS-related illness (the delayed treatment group).

In May 2011, the study reported initial success, showing for the first time that starting HIV treatment immediately provided as much as a 96 percent reduction in the chance that the negative partner in a monogamous relationship would contract HIV from a positive partner.

But longer-term results of early start for ART remained to be seen. And with adherence—people’s ability to take their HIV meds consistently without missing doses—posing one of the major challenges for HIV treatment, further results of HPTN 052 could be of great importance. Moreover, HPTN 052 included counseling on safer sex and condom use. If the couples avoided unprotected sex during the first years of HPTN 052, but their condom use dwindled over time, later numbers could potentially show less promise.

Ninety-one percent of participants in the early treatment group had suppressed viral loads at the two-year mark, Mayer and his colleagues reported, compared with 22 percent of those in the delayed treatment group.

As for safer sex practices, Mayer and his colleagues showed that at the start of the trial, 4 percent of people living with HIV in the early treatment group and nearly 6 percent in the delayed arm self-reported unprotected vaginal intercourse (UVI) with their primary partner within the past week. At three months, a little under 3 percent of participants in the early group, compared with a full 3 percent in the delayed group, reported UVI. After two years, UVI was still being reported by 3 percent of those in the deferred group, compared with 2 percent of those in the early treatment group.

Instances of continued UVI were more common in couples where the HIV-positive partner was female.

Considering that UVI data are based on patient self-reports, Mayer and his colleagues noted the potential for inaccurately low percentages. “Pregnancies did occur [among participants], and we have to analyze these immaculate conceptions,” Mayer quipped. But, he added, the researchers assume that people’s desire to lie about behavior did not increase over time.

“Participants developed close relationships with the HPTN 052 staff,” Mayer said, “because retention in care was important. There was no attempt to increase the level of safe sex and adherence counseling, but trust was built over time.” That means, he said, that participants were likely to report their behaviors honestly.

Search: hiv, hptn 052, hiv prevention trials network, mayer, treatment as prevention, viral load, safer sex, aids 2012

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The AIDSmeds team reviews all comments before they are posted. Please do not include ":" "@" "<" ">" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Quick Links
About HIV and AIDS
The Cure
Lab Tests
Clinical Trials
HIV Meds
Starting Treatment
Switching Treatment
Drug Resistance
Side Effects
Hepatitis & HIV
Women & Children
Fact Sheets
Treatment News
Community Forums
Conference Coverage
Health Services Directory
POZ Magazine
AIDSmeds on Twitter

Conference Coverage

XX International AIDS Conference
(AIDS 2014)
Melbourne, Australia
July 20 - 25, 2014

21st Conference on Retroviruses and Opportunistic Infections
(CROI 2014)
Boston, MA
March 3 - 7, 2014

7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
(IAS 2013)
Kuala Lumpur, Malaysia
June 30 - July 3, 2013

more conference coverage

[ about AIDSmeds | AIDSmeds advisory board | our staff | advertising policy | advertise/contact us]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.